Vaxart generated $72.4 million in revenue during Q3 2025, largely from BARDA-related contracts. Despite higher R&D expenses due to clinical trial activity, the company reported a narrower net loss of $8.1 million. A new license deal with Dynavax extended its cash runway into Q2 2027.

Vaxart experienced a significant increase in revenue during the second quarter of 2025, primarily driven by government contracts. The company continued to advance its oral vaccine platform with positive topline data for its norovirus vaccine and ongoing work on its COVID-19 and avian influenza programs. Despite the revenue growth, Vaxart reported a net loss, though it was a smaller loss compared to the same period last year.

Vaxart significantly grew its revenue in Q1 2025 due to BARDA funding, despite higher R&D expenses for ongoing vaccine programs. The company reduced its net loss compared to the prior year and maintains a cash runway into 2026.

Vaxart reported a net loss of $66.9 million for the full year 2024, an improvement from the $82.5 million net loss in 2023. Total revenue for 2024 was $28.7 million, primarily driven by government contracts. The company initiated a Phase 1 clinical trial for its second-generation oral norovirus vaccine and continues follow-up for its COVID-19 Phase 2b trial.

Vaxart reported its Q3 2024 financial results, highlighting the ongoing progress with the COVID-19 vaccine program, including the near completion of enrollment for the sentinel cohort in the Phase 2b study. The company also received feedback from the FDA on its norovirus program and is evaluating next steps.

Vaxart reported its Q2 2024 financial results, securing a significant BARDA contract of up to $453 million for a Phase 2b trial of its oral COVID-19 vaccine. The company also reported positive Phase 1 data for its bivalent norovirus vaccine candidate and extended its cash runway.

Vaxart announced positive topline results from its Phase 1 trial of an oral pill bivalent norovirus candidate focused on lactating mothers. They also anticipate initiating a Phase 2b study evaluating their XBB COVID-19 vaccine candidate as early as the second quarter of 2024.

Vaxart reported a net loss of $82.5 million for the full year 2023, compared to $107.8 million for the full year 2022. Revenue for the full year 2023 was $7.4 million, compared to $0.1 million for 2022. Cash, cash equivalents and investments totaled $39.7 million as of December 31, 2023.

Vaxart announced its Q3 2023 financial results, highlighting topline data from Phase 2 trials of its norovirus program. The company's monovalent norovirus candidate showed potential in reducing norovirus infection, acute gastroenteritis, and viral shedding. Vaxart ended the quarter with $53.0 million in cash, cash equivalents, restricted cash and marketable securities, anticipating cash runway into Q3 2024.

Vaxart reported a revenue of $1.4 million and a net loss of $22.6 million for the second quarter of 2023. The company's cash runway has been extended into Q3 2024.